Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
Holding SAGE?
Track your performance easily
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.62 - $28.26
Previous Close$5.47
Volume329.87K
Average Volume (3M)733.28K
Market Cap
$334.62M
Enterprise Value-$224.26M
Total Cash (Recent Filing)$569.15M
Total Debt (Recent Filing)$10.27M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 19, 2025EPS Estimate
-$1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.58
Shares Outstanding61,173,263
10 Day Avg. Volume810,397
30 Day Avg. Volume733,284
Standard Deviation0.16
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.54
Price to Sales (P/S)2.82
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-8.72
Enterprise Value/Gross Profit-2.59
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$10.07Price Target Upside84.10% Upside
Rating ConsensusHold
Number of Analyst Covering18
SAGE Therapeutics News
Bulls Say, Bears Say
Bulls Say
Product LaunchEarly signs suggest payer coverage seems to be relatively lenient for Zurzuvae, which could encourage its use.
Sales GrowthZurzuvae sales came in at $22.1mn, representing ~49% sequential growth over the previous quarter.
Strategic ExpansionAdditional sales representatives have been added to the Zurzuvae field force, with anticipated sales benefits from this expansion.
Bears Say
Clinical TrialsDalzanemdor fails to provide a signal on the primary or key secondary endpoints in the DIMENSION study in Huntington's Disease, marking the fourth clinical setback for Sage in the last nine months.
Financial UncertaintyVisibility around how SAGE might put its $569mn in cash to work remains poor.
Regulatory ChallengesThere is a black box warning against driving for at least 12 hours after each daily dose of the 14-day therapy for Zurzuvae, which may limit its use.
---
Ownership Overview
1.60% Insiders
20.11% Mutual Funds
27.50% Other Institutional Investors
34.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $4.62 and its highest was $28.26 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Feb 19, 2025 which is in 56 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Oct 29, 2024. The company reported -$1.53 earnings per share for the quarter, beating the consensus estimate of -$1.542 by $0.012.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.53.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 61,173,264 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.53 in its last earnings report, beating expectations of -$1.542. Following the earnings report the stock price went down -24.057%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 3M.
---
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q3 2024
0:00 / 0:00
---
SAGE Stock 12 Month Forecast
Average Price Target
$10.07
▲(84.10% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+2.61%
reiterated a sell rating last month
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.61% per trade.
---